Generali Investments Towarzystwo Funduszy Inwestycyjnych Buys 304 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 27.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,401 shares of the biopharmaceutical company’s stock after buying an additional 304 shares during the period. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Regeneron Pharmaceuticals were worth $998,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Proficio Capital Partners LLC increased its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $127,489,000. KBC Group NV increased its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock valued at $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares during the last quarter. Finally, State Street Corp boosted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6 %

Shares of NASDAQ REGN opened at $702.78 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The firm has a 50 day moving average price of $698.57 and a two-hundred day moving average price of $873.11. The stock has a market cap of $76.83 billion, a P/E ratio of 18.36, a price-to-earnings-growth ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same period in the prior year, the company posted $11.86 EPS. The company’s revenue was up 10.3% on a year-over-year basis. As a group, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. TD Cowen cut their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research report on Tuesday, February 4th. Robert W. Baird cut their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research note on Wednesday, January 8th. Finally, Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $973.13.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.